EP2528595B1 - Composés destinés à être utilisés dans le traitement de maladies - Google Patents

Composés destinés à être utilisés dans le traitement de maladies Download PDF

Info

Publication number
EP2528595B1
EP2528595B1 EP11704168.1A EP11704168A EP2528595B1 EP 2528595 B1 EP2528595 B1 EP 2528595B1 EP 11704168 A EP11704168 A EP 11704168A EP 2528595 B1 EP2528595 B1 EP 2528595B1
Authority
EP
European Patent Office
Prior art keywords
compound
hydrazide
epo
phenylaminoethane
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP11704168.1A
Other languages
German (de)
English (en)
Other versions
EP2528595A1 (fr
Inventor
Andreas Kubin
Paul FURTMÜLLER
Gerhard Wolber
Daniela Schuster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INOXIA LIFESCIENCES GmbH
Original Assignee
INOXIA LIFESCIENCES GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INOXIA LIFESCIENCES GmbH filed Critical INOXIA LIFESCIENCES GmbH
Priority to EP15173989.3A priority Critical patent/EP2965755A1/fr
Publication of EP2528595A1 publication Critical patent/EP2528595A1/fr
Application granted granted Critical
Publication of EP2528595B1 publication Critical patent/EP2528595B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the subject invention relates to compounds for the treatment of inflammatory diseases associated with eosinophilic peroxidase and wherein the inflammatory disease is selected from the group consisting of bronchial asthma, cystic fibrosis, rhinitis, sinusitis and Churg-Strauss syndrome.
  • Human enzymes of the class of peroxidases are part of the non-specific immune defense. They are released in high concentrations in defense against pathogenic microorganisms and catalyze various oxidation reactions of biomolecules, thereby inactivating invaders, such as bacteria and viruses. However, overproduction of these proteins often leads to oxidative damage to the body's own tissues and inflammation is the result.
  • EPO Smoker's lung COPD
  • MPO Alzheimer MPO Multiple sclerosis MS
  • EPO atherosclerosis MPO
  • Cystic fibrosis EPO Ulcerative colitis
  • EPO Mastidia vet. Med.
  • LPO Cancer after infections
  • EPO Hypertension NO signal
  • the EPO is considered the main cause of many diseases, especially the chronic course of bronchial asthma. With a well-tolerated inhibitor, a true cure for chronic bronchial asthma could be provided for the first time. The same applies to cystic fibrosis and other inflammatory processes in which EPO is the main causative agent. These serious and in the western world strongly increasing illnesses show mostly a chronic course and could be treated so far only with very small success.
  • EPO eosinophil peroxidase
  • this EPO / H 2 O 2 system makes use of the physiological role of the enzyme (defense against pathogens), on the other hand it causes nonspecific and specific cell damage.
  • Unspecific tissue damage involves the destruction of cells / cell walls because EPO is able to penetrate the lipid membrane of cells because of its very high positive charge (pI> 11). EPO therefore destroys cells and tissues on the way to the target sites of the infection, causing inflammation out.
  • eosinophils contribute to the pathogenesis of allergen-driven diseases, such as bronchial asthma.
  • Bronchial asthma is referred to as inflammation or increased sensitivity of the mucous membranes of the bronchi, which leads to constriction of the respiratory tract.
  • This disease is based on the stimulation of certain immune cells, so-called mast cells, via cytokines, such as interleukin 5 (IL 5).
  • IL 5 interleukin 5
  • mast cells and eosinophilic granulocytes are attracted to the bronchial area. These cells release substances (especially histamine) that, among other things, contract the airway muscles and stimulate mucus production in the lungs.
  • EPO enzyme intermediate
  • H 2 O 2 a range of aggressive oxidation products of EPO and diffusible free radicals produced in the enzymatic reaction system EPO / H 2 O 2 .
  • EPO is able to oxidize diverse small molecules.
  • These physiologically relevant enzyme substrates include nitrite (NO 2 - ), bromide (Br - ) and the pseudohalide thiocyanate (SCN - ).
  • the result is highly reactive substances such as nitrogen dioxide radicals (NO 2 ⁇ ), hypobromite ( - OBr) and hypothiocyanate ( - OSCN) or cyanate ( - OCN).
  • the biological consequences of the EPO / H 2 O 2 system are strongly substrate-specific.
  • the physiological serum concentration of SCN - much higher (or may be dietary favorably influenced be) than those of Br - or NO 2 - .
  • the oxidation product - OSCN activates the transcription factor NF- ⁇ B much more strongly than NO 2 ⁇ and therefore acts pro-inflammatory in the MAP kinase system ( Wang, J. et al. Arch Biochem Biophys 445 (2006) 256-260 ).
  • these highly active reaction products function as part of the passive immune defense and attack large parasites that have entered the body, thereby fulfilling the physiological role of EPO.
  • EPO is involved in the biochemistry of the vasoactive, ie vasodilator, substance nitric oxide (NO), which plays an essential role in angiogenesis, regulation of blood pressure, dilatation of the bronchi (eg in neonates) as well as other physiological phenomena. It is believed that NO is oxidized by EPO Compound I and Compound II when NO + is released and reacts with superoxide to form peroxynitrite (ONOO - ). This highly reactive compound (a marker of oxidative stress) in turn attacks lipids and proteins, producing nitrotyrosines and lipid peroxides.
  • NO substance nitric oxide
  • eosinophil peroxidase or their fingerprint of reaction products (e.g., brominated lipids and proteins) correlate with the degree of the disease.
  • reaction products e.g., brominated lipids and proteins
  • eosinophilic blood cells and eosinophil peroxidase are found in blood, sputum, bronchial tissue, and bronchoalveolar lavage of asthmatics and are used today as a direct, quantifiable marker of asthma in medicine as well as an indirect indicator of inflammation and patient response to asthma. therapies.
  • the WO 2009/145360 relates to phenyl or thiophene derivatives, which can also be used for the treatment of bronchial asthma.
  • the WO 2004/080377 discloses phenylhydrazides which are capable of modulating potassium channels in cells, thereby, inter alia, treating diseases such as bronchial asthma.
  • the present invention relates to compounds having the general formula (III): for use in the treatment and / or prevention of inflammatory diseases associated with eosinophil peroxidase, wherein R 1 is NH, R 2 , R 3 , R 4 , R 5 and R 6 are independently H, OH, F, Cl, Br, I or a C 1 to C 5 alkyl group and R 7 is H, OH, NH 2 , NH-NH 2 or CH 3 , and wherein the inflammatory disease is selected from the group consisting of bronchial asthma, cystic fibrosis, rhinitis, sinusitis and Churg-Strauss syndrome.
  • the present invention is based on hydrazides having the general formula (I): for the treatment and / or prevention of diseases, in particular inflammatory diseases, which are associated with eosinophilic peroxidase, where R X is a heterocyclic compound (heterocyclic radical), such as pyridine, indole, pyrazole or pyrimidine, or an aromatic compound (aromatic Radical), such as naphthol, benzene or phenylaminoethane.
  • heterocyclic radical such as pyridine, indole, pyrazole or pyrimidine
  • aromatic compound aromatic Radical
  • the free terminal amino group is advantageous, which acts as an electron acceptor.
  • Substituent R 1 is NH and the substituents R 2 , R 3 , R 4 , R 5 and R 6 are independently H, OH, F, Cl, Br, I or a C 1 to C 5 alkyl group.
  • EPO eosinophil peroxidase
  • the compounds according to the invention are selective for eosinophil peroxidase (occurrence in white blood cells) and the homologous lactoperoxidase (occurrence in breast milk and in saliva). However, these compounds are not able to inhibit myeloperoxidase, in particular human myeloperoxidase, to the same extent, which allows the targeted use of these compounds as a specific drug, selective against EPO.
  • the compounds of the invention are well known in the art and are prepared by known methods (see, eg Finger, GC. et al. J Am Chem Soc 81 (1959) 94-101 ). Most N-arylglycines, as well as their esters, hydrazides, and other derivatives, are made to bioassay their tuberculostatic potential. p-Alkylanilines and p-cyclohexylanilines are prepared by Beckmann rearrangement of oximes of the corresponding p-substituted acetophenones.
  • p-Alkoxyanilines are prepared by alkylation of p-benzalaminophenol with alkyl halides and NaOH in aqueous ethanol with subsequent hydrolysis of the aldimines with HCl. ( Tien, NB. et al. Org Chem 23 (1958) 186-8 ).
  • inflammatory diseases associated with eosinophil peroxidase refers to diseases and conditions that are due to increased activity of the EPO in a subject (see, eg, US Pat Davies, MJ. et al. Antioxidants & Redox Signaling 10 (2008) 1199-1234 ; Wang, J. et al. Arch Biochem Biophys 445 (2006) 256-260 ; Mitra, SN. et al. Redox Report 5 (2000) 215-224 ).
  • diseases are well known to the person skilled in the art, as is the case is discussed at the beginning.
  • the association between EPO activity and diseases that result from EPO activity is also well known in the art.
  • 3-bromotyrosines could be detected by GC-MS (gas chromatography-mass spectrometry), which were obtained by modifying proteins using - OBr, an EPO oxidation product ( Aldridge, CJ. et al. Free Radical Biology & Medicine 33 (2002) 847-856 ).
  • Tumors can also be the result of increased EPO activity, as this leads to oxidative damage to the DNA, which is caused by infections by reactive oxygen species (eg bromo nucleotides, singlet oxygen) (eg Schistosoma haematobium and bladder cancer, or Opisthorcis vicerrini and cholangiocarcinoma (bile duct cancer ) ( Mitra et al. Redox Report 5 (2000) 215-224 ).
  • reactive oxygen species eg bromo nucleotides, singlet oxygen
  • eg Schistosoma haematobium and bladder cancer, or Opisthorcis vicerrini and cholangiocarcinoma (bile duct cancer ) Mitra et al. Redox Report 5 (2000) 215-224 .
  • An alternative term for "inflammatory diseases associated with eosinophil peroxidase” are inflammatory diseases that are based on an increased activity of EPO in the body, wherein the increased activity refers to an average individual who
  • the compounds of the invention include i.a. pharmaceutically acceptable acid addition salts, which according to the invention are to be understood as meaning those salts selected from the salts of hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, acetic, fumaric, succinic, lactic, citric, tartaric and maleic acids, the salts of hydrochloric acid, Hydrobromic acid, sulfuric acid, phosphoric acid, and acetic acid are particularly preferred.
  • R 7 has a free amino group, preferably a hydrazide group.
  • the amino groups of such compounds having the general formulas (I) or (IIIa) and (IV) are advantageous for its action as an EPO inhibitor. That is, the compounds of the invention should have the free amino group at the site of action. However, it is possible to increase the compatibility of the compounds of the invention to provide the amino group with a protecting group, which is optionally removed at the site of action (prodrug concept).
  • R 7 of the compound of the general formula (III) may also be an H, OH or CH 3 radical. Such compounds are also able to inhibit eosinophilic peroxidase with high efficiency.
  • R 1 is NH, the hydrazide having the general formula (IV):
  • the C 1 to C 5 alkyl group is selected from the group consisting of CH 3 and CH 2 CH 3 .
  • R 1 is NH
  • R 2 is F or H
  • R 3 is Cl, Br or H
  • R 4 is Cl
  • F CH 3 or H
  • R 5 and R 6 are H
  • R 7 is OH or NH -NH 2 .
  • the compound (III) according to the invention has the following substituents (see Table A): Table A: No. R 1 R 2 R 3 R 4 R 5 R 6 R 7 1 NH H H F H H H NH-NH 2 2 NH H H Cl H H H NH-NH 2 3 NH F H H H H NH-NH 2 4 NH H Cl F H H NH-NH 2 5 NH H br H H H NH-NH 2 6 NH H H H H H H NH-NH 2 7 NH F H F H H H NH-NH 2 8th NH H H CH 3 H H H NH-NH 2 9 NH F Cl H H H NH-NH 2 10 NH Cl H H H H NH-NH 2 11 NH F H H Cl H NH-NH 2 12 NH F H Cl H H H NH-NH 2 13 NH F H H H Cl NH-NH 2 14 NH H Cl H H H NH-NH 2 15 NH H F H H H NH-NH 2 16 NH F F H
  • the compound is selected from the group consisting of 2-fluoro-phenylaminoethane-hydrazide, 4-fluoro-phenylaminoethane-hydrazide, 2,4-di-fluoro-phenylaminoethane-hydrazide, 4-chloro-phenylaminoethane Hydrazide, 3-chloro-4-fluoro-phenylaminoethane hydrazide, 3-bromo-4-fluoro-phenylaminoethane hydrazide, 4-methyl-phenylaminoethane hydrazide, phenylaminoethane hydrazide, N- (2-fluorophenyl) glycine, and 2- [ (4-chlorophenyl) amino] acetic acid.
  • the compounds according to the invention can be used to treat inflammatory diseases whose cause is found in an excessive EPO activity.
  • Eosinophilic granulocytes and EPO are part of the non-specific immune defense. Especially in inflammatory processes accumulations of these white blood cells, which can also cause chronic inflammation.
  • the inflammatory disease is selected from the group consisting of bronchial asthma, cystic fibrosis, rhinitis, sinusitis and Churg-Strauss syndrome.
  • EPO eosinophils peroxidase
  • illness entity literature bronchial asthma Chronic inflammatory respiratory disease, allergy (1), (4), (7), (15) sinusitis Chronic inflammation of the sinuses / nasal catarrh, runny nose (9), (10) rhinitis Nasal catarrh, runny nose (15), (16) Cystic fibrosis Genetic respiratory disease (1) Churg-Strauss syndrome Inflammation of small blood vessels: clinical picture of rhinitis / asthma (14) (1) Davies MJ, et al. Antioxidants & Redox Signaling. 10, 2008: 1199-1234 , (4) Mitra SN, et al. Redox Rep.
  • EPO and / or their reaction products could be detected in various inflamed organs and tissues as well as secretions derived therefrom.
  • this proves the passive immune response of EPO in the context of phagocytosis, on the other hand, the tissue-destroying effect of EPO and its reaction products is also massively demonstrated.
  • EPO could be radioimmunologically detected as well as 3-bromotyrosine by means of gas chromatography mass spectrometry (GC-MS) ( Aldridge et al. Free Radical Biology & Medicine 33 (2002) 847-856 ).
  • GC-MS gas chromatography mass spectrometry
  • the compounds according to the invention can be administered in different ways. Depending on the disease, the compounds can be administered systemically or locally.
  • the compounds according to the invention in particular phenyl-amino-ethane-hydrazide (PAEH) or its derivatives, are therefore preferably formulated in an intravenous, intracavitary, oral, intraperitoneal, inhalational and topical administration form.
  • PAEH phenyl-amino-ethane-hydrazide
  • the invention Compound, in particular phenyl-amino-ethane-hydrazide or its derivatives, preferably in the form of an infusion, tablet, capsule, cream, gel, emulsion or a plaster before.
  • the pharmaceutical composition according to the invention comprises, in addition to the compounds according to the invention, auxiliaries, such as e.g. Disintegrants and stabilizers, carriers and diluents.
  • auxiliaries such as e.g. Disintegrants and stabilizers, carriers and diluents.
  • customary auxiliaries, carriers and diluents are gelatin, natural sugars (such as cane sugar or milk sugar, lecithin, pectin, starch (eg corn starch) and starch derivatives, cyclodextrins and cyclodextrin derivatives, polyvinylpyrrolidone, gelatin, gum arabic, alginic acid, tylose, talc, lycopodium, Silica (eg colloidal), levulose, tragacanth, sodium chloride, stearates, magnesium and calcium salts of fatty acids having 12 to 22 carbon atoms, in particular the saturated (eg stearates), polyethylene glycol having an average molecular weight between 200 and 20,000, preferably between 200 and 5,000, in particular between 200 and 1,000, or mixtures thereof and / or polymers of vinylpyrrolidone and / or copolymers of vinylpyrrolidone and vinyl acetate, esters of aliphatic saturated or uns
  • Another aspect of the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising at least one compound as described herein for use in the treatment and / or prevention of inflammatory diseases associated with eosinophilic peroxidase, and wherein the inflammatory disease is selected from the group consisting of asthma bronchial, cystic fibrosis, rhinitis, Sinusitis and Churg-Strauss syndrome.
  • the pharmaceutical composition of the invention is preferably in the form of an infusion, tablet, capsule, cream, gel, emulsion or patch.
  • Yet another aspect of the present invention relates to the use of the compounds of the present invention for the manufacture of a medicament for the treatment and / or prevention of inflammatory diseases associated with eosinophilic peroxidase and wherein the inflammatory disease is selected from the group consisting of Bronchial asthma, cystic fibrosis, rhinitis, sinusitis and Churg-Strauss syndrome.
  • Another aspect of the present invention relates to a method for the treatment and / or prevention of inflammatory diseases associated with eosinophilic peroxidase and wherein the inflammatory disorder is selected from the group consisting of bronchial asthma, cystic fibrosis, rhinitis, sinusitis and churg -Strauss syndrome, by administering one or more of the compounds of the invention.
  • IC 50 is the inhibitor concentration that is needed to inhibit an enzyme, here EPO, to 50%. This concentration is determined UV / spectrophotometrically at 290 nm at steady state with a monochlorodimedone MCD assay.
  • Eosinophilic peroxidase forms a variety of different enzyme intermediates and is able to catalyze a large number of redox reactions.
  • the physiological role of EPO is the oxidation of bromide or thiocyanate to hypobromous acid or Hypothiocyante (also known as halogenation cycle). And it is precisely this reaction to inhibit it.
  • hypobromous acid or Hypothiocyante also known as halogenation cycle.
  • the enzyme can also undergo the so-called peroxidase cycle.
  • Table 2 shows, on the basis of several examples, the selectivity of the phenyl-amino-ethane hydrazides for EPO (and also for the homologous LPO), but not for MPO: ⁇ i>
  • Table 2 ⁇ / i>
  • the compound (3) 2-fluorophenyl-NH-ethane hydrazide has a IC 50 value for EPO of 0.009 ⁇ M, but for MPO a significantly higher IC 50 value of 1.900 or 8.800 ⁇ M. That is, this substance is a very good inhibitor for EPO, but not for MPO from the same family of human peroxidase enzymes.
  • Phenyl-amino-ethane hydrazide shows an IC 50 value of 2.229 ⁇ M. This potential can already lead, with good tolerability as an inhibitor for therapeutic use.
  • Example Number (3) shows 2-fluorophenyl-NH-ethane hydrazide more than 200 times potential with an IC 50 value of 0.009 ⁇ M. As a result, very low therapeutic concentrations are possible, thereby minimizing any unwanted side effects.
  • Isoniazid was found to have an IC 50 value of 6.04 ⁇ M.
  • iproniazide N'-isopropylisonicotinohydrazide
  • animal models can be used. With the help of animal models, it is possible to prove experimentally to what extent pharmacologically active substances have the corresponding effect.
  • T-helper 2 (Th2) cells induce interleukin release, especially IL-5, which causes the release of eotaxins. These lead to the migration of eosinophils granulocytes to the lung site.
  • the increased allergic IgE levels and IgE receptors on the eosinophils cells lead to degranulation and release of proteins with a 60% share of EPO.
  • the EPO catalyzes the oxidation of halides and thiocyanate to produce highly reactive oxidation products that are released to repel parasites and microorganisms, but also (in the case of asthma and other chronic diseases) also tissue destroying.
  • Balb / c mice weighing 18-21 g are kept in a one-week acclimatization phase.
  • asthma allergic airway inflammation
  • AHR acute airway hyperresponsivesnes
  • eosinophilic airway inflammation Johnson et al. 2004, Am J Respir Crit Care Med 169: 378-385 ; Johnson et al. 2008, Am J Physiol Cell Mol Physiol 295: L780-L788 ).
  • Inflammation parameters eosinophils and EPO in the BALB (bronchioalveolar fluid) supernatant are finally measured by ELISA.
  • EPO bronchioalveolar fluid
  • the therapy group receives the compounds of the invention (1 - 10 mg / kg bw daily), while the control group gets a placebo.
  • the parameters for the development of the allergy and chronic inflammation of the respiratory tract and lungs include the number of exacerbations (severe seizure) and the extent of the AHR.
  • a third group may be treated conventionally with dexamethasone (and others).
  • the effects of the compounds according to the invention in diseases of the sinuses and the hyphae can be determined with the same animal model as bronchial asthma.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (12)

  1. Composé de formule générale (III) :
    Figure imgb0022
     pour son utilisation dans le traitement et/ou la prévention de maladies inflammatoires qui sont associées à la peroxydase éosinophile, dans lequel
    R1 est NH,
    R2, R3, R4, R5 et R6 sont, indépendamment les uns des autres, H, OH, F, Cl, Br, I ou un groupe alkyle en C1 à C5 et
    R7 est H, OH, NH2, NH-NH2 ou CH3, et dans lequel
    la maladie inflammatoire est choisie dans le groupe consistant en l'asthme bronchique, la fibrose kystique, la rhinite, la sinusite et le syndrome de Churg-Strauss.
  2. Composé pour son utilisation selon la revendication 1, caractérisé en ce que R7 est NH-NH2 et le composé présente la formule générale (IV)
    Figure imgb0023
  3. Composé pour son utilisation selon la revendication 1 ou 2, caractérisé en ce que le groupe alkyle en C1 à C5 est choisi dans le groupe consistant en CH3 et CH2CH3.
  4. Composé pour son utilisation selon l'une des revendications 1 à 3, caractérisé en ce que R1 est NH, R2 est F ou H, R3 est Cl, Br ou H, R4 est Cl, F, CH3 ou H, R5 et R6 sont H et R7 est OH ou NH-NH2.
  5. Composé pour son utilisation selon l'une des revendications 1 à 4, caractérisé en ce que le composé est choisi dans le groupe consistant en l'hydrazide de 2-fluoro-phénylaminoéthane, l'hydrazide de 4-fluoro-phénylaminoéthane, l'hydrazide de 2,4-di-fluorophényl-aminoéthane, l'hydrazide de 4-chloro-phénylaminoéthane, l'hydrazide de 3-chloro-4-fluoro-phénylaminoéthane, l'hydrazide de 3-bromo-4-fluoro-phénylaminoéthane, l'hydrazide de 4-méthyl-phénylaminoéthane, l'hydrazide de phénylaminoéthane, la N-(2-fluorophényl)glycine et l'acide 2-[(4-chlorophényl)amino]acétique.
  6. Composé pour son utilisation selon l'une des revendications 1 à 5, caractérisé en ce que le composé est prévu sous une forme galénique intraveineuse, intracavitaire, orale, intrapéritonéale, pour inhalation et topique.
  7. Composé pour son utilisation selon l'une des revendications 1 à 6, caractérisé en ce que le composé se présente sous la forme d'une perfusion, d'un comprimé, d'une gélule, d'une crème, d'un gel, d'une émulsion ou d'un patch.
  8. Composé pour son utilisation selon l'une des revendications 1 à 7, caractérisé en ce que le composé est administré en une quantité de 0,01 à 2 000 mg/kg de poids corporel, de préférence de 0,1 à 1 000 mg/kg de poids corporel, de manière encore davantage préférée de 0,1 à 500 mg/kg de poids corporel.
  9. Composition pharmaceutique, comprenant au moins un composé selon l'une des revendications 1 à 5, pour son utilisation pour le traitement et/ou la prévention de maladies inflammatoires qui sont associées à la peroxydase éosinophile, dans laquelle la maladie inflammatoire est choisie dans le groupe consistant en l'asthme bronchique, la fibrose kystique, la rhinite, la sinusite et le syndrome de Churg-Strauss.
  10. Composition pharmaceutique, pour son utilisation selon la revendication 9, caractérisée en ce que le composé est prévu sous une forme galénique intraveineuse, intracavitaire, orale, intrapéritonéale, pour inhalation et topique.
  11. Composition pharmaceutique, pour son utilisation selon la revendication 9 ou 10, caractérisée en ce que le composé se présente sous la forme d'une perfusion, d'un comprimé, d'une gélule, d'une crème, d'un gel, d'une émulsion ou d'un patch.
  12. Utilisation d'une composition selon l'une des revendications 1 à 5, pour inhiber la peroxydase éosinophile in vitro.
EP11704168.1A 2010-01-29 2011-01-28 Composés destinés à être utilisés dans le traitement de maladies Not-in-force EP2528595B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP15173989.3A EP2965755A1 (fr) 2010-01-29 2011-01-28 Liaisons destinees a etre utilisees dans le traitement de maladies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0012210A AT509045B1 (de) 2010-01-29 2010-01-29 Verbindungen zur behandlung von asthma bronchiale
PCT/AT2011/000050 WO2011091461A1 (fr) 2010-01-29 2011-01-28 Composés destinés à être utilisés dans le traitement de maladies

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP15173989.3A Division-Into EP2965755A1 (fr) 2010-01-29 2011-01-28 Liaisons destinees a etre utilisees dans le traitement de maladies
EP15173989.3A Division EP2965755A1 (fr) 2010-01-29 2011-01-28 Liaisons destinees a etre utilisees dans le traitement de maladies

Publications (2)

Publication Number Publication Date
EP2528595A1 EP2528595A1 (fr) 2012-12-05
EP2528595B1 true EP2528595B1 (fr) 2015-08-05

Family

ID=43707937

Family Applications (2)

Application Number Title Priority Date Filing Date
EP15173989.3A Withdrawn EP2965755A1 (fr) 2010-01-29 2011-01-28 Liaisons destinees a etre utilisees dans le traitement de maladies
EP11704168.1A Not-in-force EP2528595B1 (fr) 2010-01-29 2011-01-28 Composés destinés à être utilisés dans le traitement de maladies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP15173989.3A Withdrawn EP2965755A1 (fr) 2010-01-29 2011-01-28 Liaisons destinees a etre utilisees dans le traitement de maladies

Country Status (12)

Country Link
US (1) US20130065962A1 (fr)
EP (2) EP2965755A1 (fr)
JP (1) JP5788907B2 (fr)
KR (1) KR20120128644A (fr)
CN (2) CN104958286B (fr)
AT (1) AT509045B1 (fr)
AU (1) AU2011208939B2 (fr)
BR (1) BR112012018772A2 (fr)
CA (1) CA2788326A1 (fr)
MX (1) MX2012008815A (fr)
SG (1) SG182786A1 (fr)
WO (1) WO2011091461A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2882430A4 (fr) * 2012-08-10 2016-09-28 Univ Mcmaster Inhibiteurs antibactériens
TWI689490B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
CN106999458B (zh) * 2014-10-10 2021-04-13 普罗米蒂克医药Smt有限公司 用于预防和治疗糖尿病的经取代芳族化合物和药物组合物
EP3323428A1 (fr) * 2016-11-17 2018-05-23 CNRS Centre National de la Recherche Scientifique Inhibiteurs sélectifs de c-flip en tant qu'agents anticancéreux

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007019A2 (fr) * 1999-07-27 2001-02-01 Zambon Group S.P.A. Utilisation de n-acetyle cysteine pour la preparation de compositions pharmaceutiques topiques destinees au traitement de pathologies allergiques des voies respiratoires

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082846A (en) 1976-11-18 1978-04-04 University Of Utah Method for treating psoriasis
EP0323590A3 (fr) 1987-12-24 1990-05-02 Ono Pharmaceutical Co., Ltd. Dérivés carbazoyliques
JPH02753A (ja) * 1987-12-24 1990-01-05 Ono Pharmaceut Co Ltd カルバゾイル誘導体、それらの製造方法およびそれらを有効成分として含有するメイラード反応阻害剤
DE69220050T2 (de) 1991-04-01 1998-01-22 Univ Duke Verfahren zur inhibierung der fibrose
US5324747A (en) * 1992-07-15 1994-06-28 Hoffmann-La Roche Inc. N-substituted anilines, inhibitors of phospholipases A2
CH683965A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
US6197743B1 (en) * 1996-07-26 2001-03-06 The Trustees Of Boston University Compositions and methods for the treatment of viral disorders
US5741926A (en) * 1997-02-12 1998-04-21 Shaman Pharmaceuticals, Inc. Aniline derivatives having antihyperglycemic activity
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
WO1999040883A2 (fr) * 1998-02-11 1999-08-19 Faller Douglas V Compositions et techniques de traitement de la mucoviscidose
JP2002524505A (ja) * 1998-09-15 2002-08-06 コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー 高血中脂質濃度に因る疾患の予防または治療のための、ケイ皮酸誘導体を含む組成物
AU2004242565A1 (en) * 1999-01-12 2005-01-27 Kenneth Blum Treatment of hypertension with compounds that inhibit the destruction of enkephalins or endorphins
EP1187817B1 (fr) 1999-05-28 2003-07-30 Cheil Jedang Corporation Derives de cathecol-hydrazone, procede de preparation correspondant, et composition pharmaceutique renfermant lesdits derives
US6444829B1 (en) 2000-07-19 2002-09-03 Hoffmann-La Roche Inc. Pyrrolidine compounds
CA2481995A1 (fr) 2002-04-08 2003-10-16 Torrent Pharmaceuticals Ltd. Thiazolidine-4-carbonitriles et analogues et leur utilisation comme inhibiteurs de dipeptidyl-peptidas
US7741352B2 (en) 2003-03-11 2010-06-22 Neurosearch A/S KCNQ channel modulating compounds and their pharmaceutical use
ES2523017T3 (es) 2004-03-03 2014-11-20 Glaxosmithkline Llc Derivados de anilina como moduladores selectivos de los receptores de andrógenos
DE102004028862A1 (de) 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
CN1686297A (zh) * 2005-04-07 2005-10-26 甘肃圣达医药科技有限责任公司 一种止咳平喘药物及其制备方法
CU23431B6 (es) * 2005-05-12 2009-10-16 Ct Ingenieria Genetica Biotech Método para la inhibición de la proliferación de células tumorales y el tratamiento del cáncer
WO2007026215A1 (fr) 2005-08-29 2007-03-08 Glenmark Pharmaceuticals S.A. Dérivés de pyrazole tels que les ligands du récepteur de cannabinoïde, compositions pharmaceutiques les contenant et procédés pour leur préparation
DE102006005179A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
CA2974246C (fr) * 2006-09-01 2020-02-25 Senhwa Biosciences, Inc. Composes heteroaryles tricycliques et leur utilisation comme modulateursde proteine
EP2142516B1 (fr) 2007-03-30 2012-12-26 Sanofi Composés d'hydrazide de pyrimidine en tant qu'inhibiteurs de pgds
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
NZ595978A (en) * 2009-05-04 2013-11-29 Prometic Biosciences Inc Substituted aromatic compounds and pharmaceutical uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007019A2 (fr) * 1999-07-27 2001-02-01 Zambon Group S.P.A. Utilisation de n-acetyle cysteine pour la preparation de compositions pharmaceutiques topiques destinees au traitement de pathologies allergiques des voies respiratoires

Also Published As

Publication number Publication date
AT509045A4 (de) 2011-06-15
JP2013518061A (ja) 2013-05-20
SG182786A1 (en) 2012-09-27
EP2528595A1 (fr) 2012-12-05
US20130065962A1 (en) 2013-03-14
BR112012018772A2 (pt) 2016-04-12
KR20120128644A (ko) 2012-11-27
WO2011091461A1 (fr) 2011-08-04
MX2012008815A (es) 2012-11-23
AT509045B1 (de) 2011-06-15
CN104958286B (zh) 2018-01-05
CN102858329B (zh) 2015-06-17
AU2011208939A1 (en) 2012-08-30
CN102858329A (zh) 2013-01-02
CA2788326A1 (fr) 2011-08-04
EP2965755A1 (fr) 2016-01-13
CN104958286A (zh) 2015-10-07
JP5788907B2 (ja) 2015-10-07
AU2011208939B2 (en) 2015-07-09

Similar Documents

Publication Publication Date Title
EP1782824B1 (fr) Compositions pharmaceutiques sous forme d'hydrogel contenant de la diamino-oxydase
EP2528595B1 (fr) Composés destinés à être utilisés dans le traitement de maladies
EP2380569B1 (fr) Osmolyte à la reduction des effects secondaires des steroïdes ou antihistaminiques
US8410068B2 (en) Compounds for the treatment or alleviation of edema, and methods for their use
EP2110132B1 (fr) Utilisation d'oxyde de deutérium en tant qu'inhibiteur d'élastase
JP2018535249A (ja) ランピルナーゼおよび／またはアンフィナーゼを使用するウイルス性結膜炎の処置
Li et al. Microglia in neuroimmunopharmacology and drug addiction
US20120283331A1 (en) Anti-Inflammatory Quinic Acid Derivatives for Radioprotection/Radiomitigation
WO2018011416A1 (fr) Utilisation pharmaceutique de l'acide bêta-d-mannuronique
WO2019043064A1 (fr) Composition pour le traitement topique de maladies inflammatoires de la peau et des muqueuses non provoquées par des micro-organismes
WO2009023943A1 (fr) Combinaison pharmaceutique, compositions à usage topique, formes pharmaceutiques et procédé de traitement d'otite aiguë ou chronique chez des animaux de compagnie
EP3585367A1 (fr) Composition renfermant du cinéol utilisée pour traiter des maladies nasales
US20190038653A1 (en) Compounds and methods for treating inflammatory diseases
WO2023202439A1 (fr) Utilisation der dérivé de composé diterpène ou de sel de celui-ci dans la préparation de médicament pour prévention et traitement d'une dermatite atopique
Asano et al. Suppressive activity of fexofenadine hydrochloride on nitric oxide production in-vitro and in-vivo
WO2023203022A1 (fr) Traitement de dermatoses neutrophiles
CN117797168A (zh) 一种隔绝过敏原的鼻腔用组合物
CN118001410A (zh) 组合物及其用途
DE102005002991A1 (de) Verfahren zur Herstellung von Albumin-Konjugaten mit Gyrasehemmern
DE102004057196A1 (de) Verfahren zur Herstellung von Albumin-Konjugaten mit Nicht-steroidalen Antirheumatika (NSAR)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120829

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20140715

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150303

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 740294

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150815

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 502011007505

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ISLER AND PEDRAZZINI AG, CH

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20150805

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151106

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150805

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150805

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150805

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151105

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150805

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150805

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150805

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151205

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150805

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151207

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150805

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150805

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150805

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150805

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150805

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150805

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150805

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502011007505

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150805

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160131

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20160509

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160128

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150805

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150805

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160128

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20170111

Year of fee payment: 7

Ref country code: DE

Payment date: 20170117

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20170125

Year of fee payment: 7

Ref country code: GB

Payment date: 20170125

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150805

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20110128

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150805

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150805

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20180124

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150805

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150805

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150805

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 502011007505

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 740294

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180128

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20180128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180801

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150805

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180128

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180131

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180131

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190131